antibody degraducer conjugates (Ubix Therapeutics/Debiopharm)

N/A

Report date: 2025/03/14 16:21:45

Base Information

Drug Nameantibody degraducer conjugates (Ubix Therapeutics/Debiopharm)
Drug Alias NameE3 ubiquitin ligase based protein degradation (Ubix Therapeutics/Debiopharm)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionUbiquitin-protein ligases modulators
TargetsUbiquitin-protein ligases
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerlandSouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUbix Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesDebiopharm International SaUbix Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A